Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 6773-6779

  Song, Hyun Jin ^a   Lee, Jun Ah ^b   Han, Euna ^c   Lee, Eui Kyung ^a  

^a Sungkyunkwan University   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Decision analysis; Markov model; Mifamurtide; Osteosarcoma; Quality adjusted life years

Indexed keywords

ANTINEOPLASTIC AGENT; MIFAMURTIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; PHOSPHATIDYLETHANOLAMINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; DEATH; DISEASE FREE SURVIVAL; DRUG EFFICACY; LIFE EXTENSION; LIFESPAN; MARKOV PROCESS MODEL; METASTASIS; OSTEOSARCOMA; POST RECURRENCE DISEASE FREE SURVIVAL; POST RECURRENCE DISEASE PROGRESSION SURVIVAL; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; STATISTICAL MODEL; SURVIVAL; ANALOGS AND DERIVATIVES; DRUG THERAPY; HUMAN; MARKOV CHAIN; PATHOLOGY;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; DRUG THERAPY; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; NEOPLASM METASTASIS; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES;

EID: 84947128974     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3405-3     Document Type: Article

References (17)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.
2. Bielack S, Carrle D, Casali PG, On behalf of the ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Supplement 4):iv137–9.
3. NCCN clinical practice guidelines in oncology: bone cancer. version 2.2012.
4. Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12(2):285–92.
5. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11.
6. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(4):633–8.
7. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115(22):5339–48.
8. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–65.
9. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–68.
10. Johal S, Ralston S, Knight C. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. Value Health. 2013;16(8):1123–32.
11. Song HJ, Lee EK, Lee JA, Kim HL, Jang KW. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis. Tumour Biol. 2014;35(9):8771–9.
12. The guideline of pharmacoeconomics in South Korea. Health Insurance Review and Assessment. 2011.
13. Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer. 2009;52:340–5.
14. Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. Oxford: Oxford University Press; 2006.
15. Complete Life Table 2010. Korean Statistical Office. http://kostat.go.kr (2010). Accessed 21 Nov 2013.
16. Yu G, Sung G. Diagnosis and treatment of osteosarcoma. Chosun Ilbo, Samsung Medical Center; 2006.
17. Lee YJ, Lee HJ, Kim DH, Lim JS, Lee JH, Park KD, et al. Outcome after relapse in childhood and adolescent osteosarcoma: single institution experience in Korea. Korean J Pediatr. 2008;51(1):78–83.